Munson Medical Center is bringing innovative brain tumor imaging technology to Northern Michigan with the adoption of FDA-approved Gleolan® (5-ALA), an optical imaging agent that helps neurosurgeons better visualize malignant glioma tissue during surgery.
Used with a specialized surgical microscope, Gleolan causes tumor cells to become fluorescent under blue light, making it easier for surgeons to identify and remove cancerous tissue that may be difficult to see. Clinical studies show fluorescence-guided surgery can significantly improve complete tumor resection rates compared to white-light microsurgery.
Justine Pearl, MD, was Munson’s first neurosurgeon to use Gleolan. “Gleolan gives us another tool to better distinguish tumor tissue during surgery, helping us achieve more complete tumor removal while preserving healthy brain tissue whenever possible,” said Dr. Pearl. “This technology expands access to advanced neurosurgical care for patients throughout Northern Michigan.”